EVOLUTION® NitrX™
DeviceEVOLUTION® NitrX™ Keeled Tibia and EVOLUTION® NitrX™ CS/CR Femur With Cruciate Sacrificing Insert
NCT Number: NCT04816773
MicroPort Orthopedics Inc. (MPO) plans to market the EVOLUTION® NitrX™ Non-Porous Keeled Tibia and EVOLUTION® NitrX™ CS/CR Non-Porous Femur with the EVOLUTION® Cruciate Sacrificing (CS) Tibial Insert globally, including in the European Union (EU). MPO is conducting this post market clinical follow-up (PMCF) study to evaluate the safety and effectiveness of the EVOLUTION® NitrX™ Non-Porous Keeled Tibia and EVOLUTION® NitrX™ CS/CR Non-Porous Femur. These components are used along with the EVOLUTION® Cruciate Sacrificing (CS) Tibial Insert components that is marketed in the European Union (EU). This type of data collection is required by regulatory authorities for all TKA devices that do not have medium to long-term clinical evidence available.
Interested in participating?
Request Info21 year and older
All sexes
Observational
MSK Doctors, The Keep Clinic, Grantham, Lincolnshire, United Kingdom
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Prospective enrollment of a previously unimplanted contralateral knee is permitted in this study provided:
Bilateral subjects can have both TKAs enrolled in the study provided:
Bilateral implantation can occur at different time periods for the same subject.
Exclusion criteria
EVOLUTION® NitrX™ Keeled Tibia and EVOLUTION® NitrX™ CS/CR Femur With Cruciate Sacrificing Insert
Time frame: 10 years post-operative
The primary endpoint is to evaluate component survivorship of the EVOLUTION® NitrX™ Non-Porous Keeled Tibia out to 10 years follow-up. Percentage of knees survived with no revisions or replacement at 10-year
Time frame: 10 years post-operative
The primary endpoint is to evaluate component survivorship of the EVOLUTION® NitrX™ CS/CR Non-Porous Femur out to 10 years follow-up. Percentage of knees survived with no revisions or replacement at 10-year.
Time frame: 10 years post-operative
The primary endpoint is to evaluate component survivorship of the EVOLUTION® NitrX™ MP CS tibial inserts out to 10 years follow-up. Percentage of knees survived with no revisions or replacement at 10-year.
Time frame: 10 years post-operative
To assess functional scores utilizing Knee Injury and Osteoarthritis Outcome Score (KOOS).
Time frame: 10 years post-operative
To assess functional scores utilizing EQ-5D-5L.
Time frame: 10 years post-operative
To assess functional scores utilizing Forgotten Joint Score (FJS).
Time frame: 10 years post-operative
To assess subject satisfaction with their TKA procedure via the Satisfaction Survey.
Time frame: 10 years post-operative
To assess the presence of radiolucencies surrounding the implanted femoral and tibial components present in each of the 17 zones.
Time frame: 1, 3, 5, 7, 10 years
To assess safety of the EVOLUTION® NitrX™ system through device-related adverse event findings and/or adverse device effects during follow-up visits.
Time frame: 10 years post-operative
To assess tolerability of the EVOLUTION® NitrX™ system service-related adverse event findings and/or adverse device effects during follow-up visits.
MicroPort Orthopedics Inc.
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07391592
Arthritis Knee, Avascular Necrosis
Fremont, California, United States
View Trial DetailsNCT05548972
Arthritis, Arthritis, Rheumatoid
Little Rock, Arkansas, United States
View Trial DetailsNCT04147559
Ankylosis, Arthritis
Scottsdale, Arizona, United States
View Trial DetailsNCT06550024
Arthritis, Connective Tissue Diseases
Birmingham, Alabama, United States
View Trial Details